Skip to main content

Table 3 Median change (interquartile range) of circulating biomarkers

From: A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer

    Baseline Six weeks Change   
Variable Treat. N Obs Median
IQR
Median
IQR
Median
IQR
Contrast1 P
IGF1 ng/mL P 25 146
(117 to 177)
151
(105 to 205)
-0.5
(-14.5 to 12)
T vs. R 0.87
  R 50 134.5
(113 to 174)
126
(104 to 157)
-10.1
(-30.4 to 13)
T + R vs. P 0.15
  T 50 137.5
(113 to 170)
137
(92.7 to 168)
-13
(-27 to 11)
  
IGFBP-3 µg/mL P 25 4.16
(3.75 to 4.76)
4.42
(3.79 to 4.84)
-0.09
(-0.29 to 0.22)
T vs. R 0.05
  R 50 4.22
(3.84 to 4.71)
4.58
(4.07 to 5.11)
0.41
(0 to 0.69)
T + R vs. P 0.22
  T 50 4.28
(3.72 to 4.73)
4.42
(3.87 to 4.78)
0.02
(-0.25 to 0.37)
  
IGF1/BP3 ratio P 25 0.18
(0.16 to 0.21)
0.18
(0.15 to 0.24)
0
(-0.03 to 0.02)
T vs. R 0.41
  R 50 0.17
(0.15 to 0.21)
0.16
(0.12 to 0.17)
-0.03
(-0.05 to 0)
T + R vs. P 0.01
  T 50 0.18
(0.15 to 0.2)
0.17
(0.13 to 0.19)
-0.01
(-0.04 to 0)
  
SHBG nmol/L P 25 65.9
(39 to 94)
53.5
(36 to 86)
-7.7
(-22 to 3.4)
T vs. R 0.92
  R 50 63.45
(43.3 to 96.4)
78.1
(50.7 to 101)
7.7
(-7.3 to 18.5)
T + R vs. P 0.32
  T 50 64.3
(47.8 to 80.4)
69.6
(51.7 to 86.8)
2.2
(-7.1 to 21.9)
  
Testosterone P 25 0.26
(0.17 to 0.34)
0.28
(0.16 to 0.35)
0.02
(-0.08 to 0.07)
T vs. R 0.90
ng/mL R 50 0.23
(0.16 to 0.32)
0.27
(0.18 to 0.36)
0.03
(-0.03 to 0.09)
T + R vs. P 0.10
  T 50 0.23
(0.19 to 0.32)
0.27
(0.22 to 0.34)
0.02
(-0.02 to 0.09)
  
Estradiol ng/mL P 25 120.3
(51.4 to 167.4)
104.35
(45.1 to 179.4)
-9.6
(-99.6 to 91)
T vs. R 0.45
  R 50 94.35
(41.9 to 147.4)
124.7
(65.5 to 209)
27
(-62.9 to 159.08)
T + R vs. P 0.05
  T 50 103.25
(61.98 to 165.5)
160.7
(70.86 to 306.4)
29.5
(-37.3 to 179.8)
  
  1. IQR, interquartile range; IGF, insulin-like growth factor; P, placebo; R, raloxifene 60 mg/day; T, tamoxifen 10 mg/week; IGFBP-3, insulin-like growth factor-binding protein 3; SHBG, sex hormone-binding globulin.
  2. *Contrast are between tamoxifen arm versus Raloxifene are and either treatment versus placebo.